Edition:
United States

TESARO Inc (TSRO.OQ)

TSRO.OQ on NASDAQ Stock Exchange Global Select Market

80.58USD
15 Dec 2017
Change (% chg)

$-3.29 (-3.92%)
Prev Close
$83.87
Open
$82.85
Day's High
$83.27
Day's Low
$77.25
Volume
705,585
Avg. Vol
286,970
52-wk High
$192.94
52-wk Low
$77.25

Select another date:

Tue, Nov 21 2017

BRIEF-Tesaro secures $500 million non-dilutive term loan financing

* Tesaro secures $500 million non-dilutive term loan financing

BRIEF-Tesaro announces European Commission approval of Zejula for women with recurrent ovarian cancer

* Tesaro announces European Commission approval of Zejula for women with recurrent ovarian cancer

BRIEF-Tesaro reports Q3 loss per share $0.47

* Q3 revenue $142.8 million versus I/B/E/S view $132.8 million

BRIEF-Opko Health licensee Tesaro announces FDA approval of Varubi IV for delayed nausea, vomiting associated with chemotherapy

* Opko Health licensee Tesaro announces FDA approval of Varubi IV for delayed nausea and vomiting associated with chemotherapy

BRIEF-Evotec, Tesaro enter partnership on novel immuno-oncology agents

* dgap-news: evotec and tesaro enter strategic partnership to discover novel immuno-oncology agents

FDA approves intravenous version of Tesaro drug for chemotherapy nausea

Tesaro Inc said on Wednesday that the U.S. Food and Drug Administration approved an intravenous version of its drug to treat chemotherapy-induced nausea and vomiting in adults.

FDA approves intravenous version of Tesaro drug for chemotherapy nausea

Oct 25 Tesaro Inc said on Wednesday that the U.S. Food and Drug Administration approved an intravenous version of its drug to treat chemotherapy-induced nausea and vomiting in adults.

Tesaro's ovarian cancer drug gets EU agency backing

A European Medicines Agency (EMA) panel recommended the approval of Tesaro Inc's key drug, niraparib, for the treatment of recurrent ovarian cancer.

Tesaro's ovarian cancer drug gets EU agency backing

Sept 15 A European Medicines Agency (EMA) panel recommended the approval of Tesaro Inc's key drug, niraparib, for the treatment of recurrent ovarian cancer.

BRIEF-Tesaro Inc Q2 loss per share $2.82

* Q2 earnings per share view $-2.49 -- Thomson Reuters I/B/E/S

Select another date: